Skip to main content
. 2021 Jun 15;11(6):2911–2927.

Figure 6.

Figure 6

Differential sensitivity of ARID1A wild-type (WT) and mutant (Mut) ovarian and gastric cancer cells to GCLC depletion. A. The graph depicts mechanistic relationship of GCLC synthetic lethality in ARID1A-deficient cancers (modified from Cancer Cell 2019) [13]. B. The alteration frequency of ARID1A in various types of cancers was analyzed by cBioPortal database. Mutations are represented in green, fusion in purple, amplification in red, deep deletion in blue, and multiple alterations in grey. C. ARID1A protein expression in ovarian and gastric cancer cells was detected by capillary Wes analysis. Black indicates ARID1A-WT cells and red indicates ARID1A-Mut cells. D. Capillary Wes analysis indicates the depletion of GCLC protein by sgRNAs. GAPDH was used as loading control. E. The effect of GCLC depletion by sgRNAs in ovarian cancer or gastric cancer cells with WT- or Mut-ARID1A was determined by CTG assay (*p-value < 0.005, **p-value < 0.05).